However, it remains unknown which transcription factors are involved in the transactivation or repression of human CD22 and whether any of these factors can explain the downregulation of CD22 protein in the B cells of CLL patients. This evidence concerns the gene CD22 and B-cell chronic lymphocytic leukemia.